On August 1, the U.S. Food and Drug Administration (FDA) released a new Guidance for Industry, “Antibacterial Therapies for Patients with an Unmet Medical Need for the Treatment of Serious Bacterial Diseases.” The guidance is not binding or legal, but is a recommendation for those working to develop or support the development of new pathogen-focused […]

Go to Original Post